Oncotelic Therapeutics Inc. (OTC:OTLC), the RNA-based therapeutics company, says it is making progress advancing its antisense oligonucleotide (ASO) platform, fueled by promising clinical data and ...

Drugmakers can now call on a host of RNA therapeutic modalities, but small-interfering RNA (siRNA) and antisense oligonucleotide (ASO) drugs still garner the highest upfront payments. Oligo therapies ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of RNA-based drugs can significantly enhance their effectiveness. These ...

RNA clusters (green colored) gradually disassemble within biomolecular condensates (magenta colored), returning the RNA to a soluble state. This occured after an antisense oligonucleotide engineered ...